Physician profile
William Littman
NPI 1285739532
$4,182.82
in general payments reported to CMS, 2019-2025
25 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $685 · 2021: $858 · 2022: $582 · 2023: $512 · 2024: $405 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.83 | 2019-2023 | |
| Janssen Biotech, INC. | $563.52 | 2019-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $425.55 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $349.43 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Pfizer INC. | $314.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.16 | 2022-2025 | Spevigo |
| Amgen INC. | $237.04 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $235.03 | 2019-2023 | Absorica Ld, Winlevi |
| Genentech USA, INC. | $188.02 | 2019-2024 | Erivedge |
| Regeneron Healthcare Solutions, INC. | $152.76 | 2021-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $117.47 | 2022-2025 | |
| Galderma Laboratories, L.P. | $106.20 | 2019-2020 | |
| Genzyme Corporation | $93.19 | 2019-2022 | |
| Biofrontera INC. | $75.31 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $53.23 | 2025 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $49.27 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.74 | 2019-2021 | |
| Strata Skin Sciences, INC. | $35.50 | 2024 | Xtrac |
| Organogenesis INC. | $27.03 | 2023 | Puraply |
| E.R. Squibb & Sons, L.L.C. | $23.06 | 2024 | Sotyktu |
| Celgene Corporation | $19.79 | 2019 | |
| Stemline Therapeutics INC. | $18.46 | 2021 | |
| Dermavant Sciences, INC. | $18.37 | 2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $14.28 | 2021 | |
| Almirall LLC | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Littman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.